Clinical Trial Detail

NCT ID NCT01827111
Title Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Ipilimumab + Nab-paclitaxel

Age Groups: adult child

No variant requirements are available.